QID 376149

Date Published: 2021-12-20

QID 376149: IBM Java Software Development Kit (SDK) Multiple Vulnerabilities (Oracle October 19 2021 CPU (1.7.0_321, 1.8.0_311))

IBM Java SDK are prone to multiple vulnerabilities that can be exploited by malicious people to disclose certain sensitive information, manipulate certain data, bypass certain security restrictions, cause a denial of service and compromise a vulnerable system.

Affected Versions:
IBM Java SDK prior to 7.0.11.0
IBM Java SDK prior to 7.1.5.0
IBM Java SDK prior to 8.0.7.0

NOTE:
CVE-2021-35560 and CVE-2021-35578 are affected to IBM Java 8 only.

QID Detection Logic (Authenticated):
The QID runs "java -version" command to check if vulnerable IBM Java is installed on the system.

Successful exploitation of these vulnerabilities may affect the Confidentiality, Integrity and Availability.

  • CVSS V3 rated as High - 7.5 severity.
  • CVSS V2 rated as Medium - 5.1 severity.
    • Solution
    Latest service refresh packs are available at IBM SDK, Java Technology Edition Download.
    Refer to Oracle October 19 2021 CPU to obtain more information.
    Vendor References

    CVEs related to QID 376149

    CVE-2021-35560 | CVE-2021-35586 | CVE-2021-35578 | CVE-2021-35564 | CVE-2021-35559 | CVE-2021-35556 | CVE-2021-35565 | CVE-2021-35588 |
    Software Advisories
    Advisory ID Software Component Link
    IBM Java SDK(Oracle October 19 2021 CPU (1.7.0_321, 1.8.0_311)) URL Logo www.ibm.com/support/pages/java-sdk-security-vulnerabilities#Oracle_October_19_2021_CPU
    By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to [email protected].